FY2025 · ended Dec 31, 2025 · Revenue $379.81M, +13.8% YoY · Filed Feb 25, 2026
Caredx, Inc. (CDNA) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $379.8 million and a net loss of $21.4 million. As of Sep 30, 2026 it held $250.5 million in cash and investments and $29.0 million in total debt.
Revenue (TTM)
$497.40M
+38.9% vs year-ago TTM
Net income (TTM)
$128.63M
+82.6% vs year-ago TTM
Operating cash flow (TTM)
$69.02M
+62.2% vs year-ago TTM
Free cash flow
$-6.04M
+58.3% vs prior year
EPS (TTM)
$2.41
+97.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
51.22M
-7.6% vs prior year
Net cash
$221.48M
as of Sep 30, 2026
Operating margin
23.4%
FY 2026
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- CDNA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1217234
- Former names
- XDx, Inc. (until Nov 15, 2011); EXPRESSION DIAGNOSTICS INC (until Dec 14, 2005)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $379.8M | $333.8M | $280.3M | $321.8M | $296.4M |
| Operating income | -$30.8M | $40.8M | -$203.4M | -$77.2M | -$29.7M |
| Net income | -$21.4M | $52.5M | -$190.3M | -$76.6M | -$30.7M |
| Diluted EPS | -$0.40 | $0.93 | -$3.54 | -$1.44 | -$0.59 |
| Operating cash flow | $42.0M | $38.0M | -$18.4M | -$25.2M | -$19.3M |
| Total assets | $413.2M | $491.1M | $466.8M | $543.0M | $566.6M |
| Total liabilities | $110.1M | $112.6M | $205.5M | $112.1M | $100.7M |
| Stockholders' equity | $303.1M | $378.4M | $261.3M | $430.9M | $465.9M |
| Cash and investments | $201.4M | $260.7M | $235.4M | $293.1M | $348.5M |
| Total debt | $26.2M | $28.4M | $34.2M | $39.0M | $21.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K/A |
Amended current report
Acquisition or sale of assets
|
Sep 16, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Acquisition or sale of assets, Regulation FD disclosure
|
Jul 7, 2026 | Jun 30, 2026 |
All 1000 Caredx, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.